

Comparative Analysis of *Candida albicans* Versus *Candida Non-albicans* Infection among Pediatric Patients at King Abdulaziz University Hospital

**Khoulood Abdulrhman Al-Sofyani^{1*}, Mohammed Shahab Uddin²,
Huda Saeed Alghamdi³ and Dalia El-Hossary^{4,5}**

¹Department of Pediatric, Pediatric Intensive Critical Care Unit, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

²Department of Pediatric, Pediatric Intensive Critical Care Unit, National Guard Health Affairs, Dammam, Kingdom of Saudi Arabia

³Consultant Medical Microbiology, Clinical and Molecular Microbiological Laboratory, Faculty of Medicine and Medical Microbiology, King Abdulaziz Hospital, Jeddah, Kingdom of Saudi Arabia

⁴Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Egypt

⁵Clinical and Molecular Microbiological Laboratory, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

***Corresponding Author:** Khoulood Abdulrhman Al-Sofyani, Department of Pediatric, Pediatric Intensive Critical Care Unit, King Abdulaziz University, Jeddah, Saudi Arabia.

Received: September 25, 2020

Published: October 28, 2020

© All rights are reserved by **Khoulood Abdulrhman Al-Sofyani, et al.**

Abstract

Background: Candidemia is one of the major causes of morbidity and mortality among critically ill pediatric patients. This study aimed to determine the prevalence of *Candida* infection, different strains, associated risk factors, and outcomes in critically ill patients with candidemia.

Method: Critically ill pediatric patients with invasive candidiasis were included in this retrospective study. Patients were 14 years or younger, admitted to King Abdulaziz University Hospital from March 2018 to February 2020.

Results: Out of 61 pediatric patients cases with candidemia, 23 (37.7%) patients were diagnosed with *C. albicans* and 38 (62.3%) with non-*albicans*. Species present in non-*albicans Candida* group included *Candida parapsilosis* 15 (24.6%), *Candida topocalis* 12 (19.7%) and *Candida glabrata* 4 (6.6%). Majority *Candida* strains were sensitive to antifungals. The main admitting diagnosis was sepsis 21 (34.4%) and the main isolation site of *Candida* species was blood. The main risk factors and predictors of candidemia were age younger than 5 months, presence of a central venous catheter, urinary catheter, using TPN, and blood products transfusion. Finally, the number of mortalities and length of ICU stay was higher among *C. albicans* patients, whereas the duration of hospitalization, broad-spectrum antimicrobial and antifungal treatment, were higher among *C. non-albicans* infected patients.

Conclusion: Although *C. albicans* infection cases are still dominant, however, the number of cases due to *C. non-albicans* infection is high. The study also highlighted some of the indicators that may help in early prophylactic intervention, which in turn can help improve the poor clinical prognostic outcome in Saudi Arabia.

Keywords: Candidemia; *Candida albicans*; *Candida non-albicans*; Risk Factors; Outcome

Abbreviations

PICU: Pediatric Critical Care Unit; TPN: Total Parenteral Nutrition; ARDS: Acute Respiratory Distress Syndrome; SBF: Sterile Body Fluids.

Introduction

During the last few decades, incidences of fungal infections have become a major health problem in hospitals, where the episodes of sepsis caused by fungi have been increasing since the early 1990s [1-3]. Fungi are ubiquitous organisms that rarely cause disease in an otherwise healthy immunocompetent hosts. Only a few (~300) fungal species, from the millions of different fungal species, are known to cause disease [4,5]. Invasive fungal infections (IFIs) occur as a result of interaction between the organism's pathogenic ability (colonization stage, propagation, adaptation, and/or dissemination) and the host immune defense and its response [4,6]. There are several reasons and risk factors that have led to a significant increase in the invasive fungal infection rate in the pediatric intensive care units over the past several decades. Several reasons for increased infections are underlying malignancy, greater use of broad-spectrum antibiotics, ICU stay for more than 72 hours, immunosuppressive therapy, presence of invasive devices such as central venous catheters (CVC), parenteral nutrition, and multiple uses of invasive procedures [7-13].

Among children, candidemia is the third most common cause of bloodstream infections in a hospital setting [7], and it also responsible for the second-highest case fatality rate in children with bloodstream infections [14].

Even with the advancement in the diagnostic procedures, development of new antifungal agents and application of newer strategies to prevent candidemia [1,6], the hematogenous candidiasis is difficult to diagnose, which ultimately results in extended hospitalization and a mortality rate of around 50%, along with high financial burden to health care systems [11,15-20]. The incidences of candidemia may significantly vary from one area to another. While the number of *Candida non-albicans* species are growing and show resistance to some antifungal agents, *C. albicans* is still the primary pathogen associated with candidemia [10,21-27]. In the last few years, several studies have confirmed the increasing cases of fluconazole and echinocandin resistant *Candida* spp. in the US and European countries [27-29]. Fluconazole resistance was reported among *C. glabrata*, *C. krusei*, *C. tropicalis* and *C. parapsilosis* strains in different regions [24,29-31].

The signs of *Candida* infection can range from a non-life threatening mucocutaneous disease to an aggressive disease that can affect any organ [32]. In children, the spread candidiasis is mostly observed in the lungs, kidney, liver, and brain, and the infection can be recurrent. The incidences of aggressive candidiasis are higher in children-mainly in the neonates-than in the adults [33]. Consequently, in the patients with amassing risk factors for candidemia, in whom the possibility for candidemia is high, clinicians order empirical treatment long before laboratory results on species identification and antibiograms are obtained as the clinicians assume that the infection is present [34,35].

Although there are many studies conducted on the prevalence of candidemia, there is limited data available in the Middle East regarding the distribution of *Candida albicans* and *Candida non-albicans* infections in the children. Therefore, we conducted this retrospective study to gain insights into the prevalence of candidiasis and its distribution in children in Saudi Arabia. The demographic data of the patients, isolation, and characterization of different *Candida* species was done, and their susceptibility to different antifungal agents was also tested. Potential risk factors associated with candidiasis were also identified. Further, we also analyzed the clinical outcome among infected patients.

Material and Methods

Ethical consideration

The study was approved by the Research Ethics Committee, Faculty of Medicine, King Abdulaziz University (Reference Number: 328-14).

Study design and setting

This study was a retrospective cross-sectional study conducted from March 2018 to February 2020 in the Pediatric Critical Care Unit (PICU) at King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia.

In this study, we recruited pediatric patients younger than or equal to 14 years who developed invasive candidiasis during their stay in the PICU. Invasive candidiasis was diagnosed upon the isolation of *Candida* spp. from blood or sterile body fluids such as peritoneal fluid, pleural fluid, cerebrospinal fluid (CSF), and synovial fluid of each patient presenting clinical features of *Candida* infection. The first episode of the *Candida* infection was analyzed for those patients who suffered multiple episodes of candidemia during their hospital stay. We excluded those patients from the study in whom *Candida* was isolated from the tissues. Detection and spe-

cies identification of the *Candida* isolates were performed according to KAUH laboratory standard protocols.

A data collection form was designed to gather patient information such as age, gender, nationality, reasons for PICU admission (medical, surgical, and trauma), and the isolation site. Predisposing risk factors included treatment with broad-spectrum antibiotics (for ≥ 7 days), central venous catheter (for > 3 days), urinary catheter (for > 1 day), mechanical ventilation (for > 2 days), multi-organ failure due to sepsis, length of ICU stay, steroid therapy, chemotherapy, blood products transfusion, presence of peritoneal tube for dialysis and or chest tube, using total parenteral nutrition (TPN). Outcome after diagnosis included length of hospital stay, survived or diseased, ventilation duration, and duration of anti-fungal treatment.

Microbiology

To perform the blood cultures, an automated blood culture system (BacT/Alert, Organon, Teknika, USA) was employed. Inoculation of the blood samples (5 ml) was done in a single pediatric bottle. Subsequently, the culture bottles were loaded into BacT/Alert blood culture and were kept until growth was detected or at the end of 5 days incubation time, if growth was not detected. All bottles that turned out to be positive were further subjected to Gram staining. Culture bottles that were positive for the yeast cells were subcultured on Sabouraud dextrose agar (SDA) (Saudi prepared media Laboratories, Riyadh, KSA). Yeast cells were then identified with the help of VITEK MS on the same day, if sufficient growth was observed on the SDA. The identification (ID) and anti-fungal-susceptibility testing of the *Candida* species was performed by using VITEK² system (bioMerieux, Inc., France) [36].

Statistical analysis

Data were analyzed with the Statistical Package for the Social Sciences (SPSS) software ver. 22.0 (IBM, Armonk, NY, USA). All collected variables were analyzed using descriptive and analytical statistics. Categorical variables were described and reported as numbers and percentages. Continuous variables were described and reported as mean \pm standard deviation. Comparisons between *C. albicans* and *C. non-albicans* groups were performed using the Chi-square test for categorical variables and by using independent t-test or one-way ANOVA for continuous variables. A p-value of ≤ 0.05 was considered significant for all statistical tests.

Results

During this study period, 61 cases with candidemia were identified. Out of the 61 pediatric patients, 23 (37.7%) were diagnosed with *C. albicans*, whereas 38 (62.3%) patients were infected with non-*albicans Candida* spp. (Table 1). Among the patients infected with *Candida*, the number of male patients were 39 (63.9%) and 22 (36.1%) were female; 16/23 (69.6%) males had *C. albicans* vs 23/38 (60.5%) had *C. non-albicans*, and 7/23 (30.4%) females had *C. albicans* vs 15/38 (39.5%) had *C. non-albicans*. Further, the patients infected with *C. albicans* were relatively younger (10.89 \pm 20.94 months) than the patients infected with *C. non-albicans* (19.5 \pm 33.68 months) The majority of the cases were found in the non-Saudi patients (~82%), in both the groups. Finally, we found that most of the cases of candidemia (44; 72.1%) were admitted for medical reasons, where 19 (82.6%) had *C. albicans* and 25 (65.8%) had *C. non-albicans*. There were no significant differences between the two groups (*C. albicans* and *C. non-albicans*) regarding all demographic data (Table 1).

Variables	Patients with candidemia Overall: N = 61 (100%)	<i>C. albicans</i> N = 23 (37.7 %)	<i>C. non-albicans</i> N = 38 (62.3 %)	Test of significance	P-value
Age (in months)	16.25 (\pm 29.63)	10.89 (\pm 20.94)	19.5 (\pm 33.68)	t = - 1.1	0.28
Gender	Males: 39 (63.9%) Females: 22 (36.1%)	Males: 16/23 (69.6%) Females: 7/23 (30.4%)	Males: 23/38 (60.5%) Females: 15/38 (39.5%)	$\chi^2 = 0.51$	0.48
Nationality	Saudi: 11 (18.0%) Non-Saudi: 50 (82.0%)	Saudi: 4/23 (17.4%) Non-Saudi:19/23 (82.6%)	Saudi: 7/38 (18.4%) Non-Saudi: 31/38 (81.6%)	$\chi^2 = 0.01$	0.99
Weight (in kg)	7.02 (\pm 6.56)	5.34 (\pm 4.73)	8.03 (\pm 7.32)	t = - 1.6	0.12
Height (in cm)	65.25 (\pm 23.24)	59.43 (\pm 20.64)	68.76 (\pm 24.27)	t = - 1.5	0.13
Medical or Surgical	Medical: 44 (72.1%) Surgical: 16 (26.2%) Burn: 1 (1.6%)	Medical: 19/23 (82.6%) Surgical: 4/23 (17.4%) Burn: 0/23 (0%)	Medical: 25/38 (65.8%) Surgical: 12/38 (31.6%) Burn: 1/38 (2.6%)	$\chi^2 = 2.27$	0.29

Table 1: Demographic characteristics of the patients with *Candida albicans* and *Candida non-albicans* infection.

Data are presented as mean \pm SD or N (%).

Among all the patients with candidemia, *C. albicans* was isolated from 23 (37.7%) patients, while non-*albicans Candida* spp. were isolated from 38 (62.3%) of the patients. Among the non-*albicans Candida* group, the majority of the fungal species isolated were *Candida parapsilosis* 15 (24.6%), *Candida tropicalis* 12 (19.7%), and *Candida glabrata* 4 (6.6%) (Table 2).

<i>Candida species</i>	N (%)
<i>Candida albicans</i>	23 (37.7%)
<i>Candida non-albicans</i>	38 (62.3%)
<i>Candida famata</i>	2 (3.3%)
<i>Candida glabrata</i>	1 (1.6%)
<i>Candida glabrata</i>	4 (6.6%)
<i>Candida guillemondii</i>	2 (3.3%)
<i>Candida lusitanae</i>	1 (1.6%)
<i>Candida parapsilosis</i>	15 (24.6%)
<i>Candida tropicalis</i>	12 (19.7%)
<i>Trichosporon asahii</i>	1 (1.6%)
Total N (%) of patients	61 (100%)

Table 2: Distribution of the various *Candida* species isolated from the patients.

The results in table 3 show the susceptibility profile of the isolated *Candida* strains tested against different types of antifungals. The antifungals agents tested were amphotericin-B, fluconazole, flucytosine, and caspofungin. We observed that all 23 (100%) isolates of *C. albicans* were sensitive against amphotericin-B and caspofungin, while 3 isolates were found to be resistant to fluconazole and 1 isolate was resistant to flucytosine (Table 3). Among *C. non-albicans* isolates, all 38 (100%) strains were sensitive to amphotericin-B and flucytosine, while 5 isolates were resistant to fluconazole and 2 isolates were resistant to caspofungin (Table 3).

Antifungal	<i>C. albicans</i> N (%) Total = 23 (100%)		<i>C. non-albicans</i> N (%) Total = 38 (100%)	
	N	% sensitive	N	% sensitive
Amphotericin-B	23	100%	38	100%
Fluconazole	20	86.90%	33	86.80%
Flucytosine	22	95.60%	38	100%
Caspofungin	23	100%	36	94.70%

Table 3: Susceptibility profile of different *Candida* species towards various antifungal agents.

Next, we analyzed the admitting diagnosis for the patients with candidemia. Sepsis (21 patients; 34.4%) was observed to be the

main admitting diagnosis, followed by abdominal surgery among 9 (14.8%) patients, and ARDS (Acute respiratory distress syndrome), cyanotic heart disease and pneumonia in 6 (9.8%) patients each (Table 4).

Admitting diagnosis	<i>C. albicans</i>	<i>C. non-albicans</i>	Total per each admitting diagnosis
	N (%)	N (%)	N (%)
Abdominal infection	0 (0%)	1 (2.6%)	1 (1.6%)
Abdominal surgery	2 (8.7%)	7 (18.4%)	9 (14.8%)
ARDS	2 (8.7%)	4 (10.5%)	6 (9.8%)
Burn	0 (0%)	1 (2.6%)	1 (1.6%)
Congestive heart failure	0 (0%)	1 (2.6%)	1 (1.6%)
Cyanotic heart disease	3 (13%)	3 (7.9%)	6 (9.8%)
Hydrocephalus	0 (0%)	2 (5.3%)	2 (3.3%)
Leukaemia	1 (0%)	0 (0%)	1 (1.6%)
Liver dysfunction	1 (4.3%)	0 (0%)	1 (1.6%)
Malignancy	1 (4.3%)	1 (2.6%)	2 (3.3%)
Meningitis	1 (4.3%)	0 (0%)	1 (1.6%)
Pneumonia	2 (8.7%)	4 (10.5%)	6 (9.8%)
Post cardiac surgery	1 (4.3%)	2 (5.3%)	3 (4.9%)
Sepsis	9 (39.1%)	12 (31.6%)	21 (34.4%)
Total (overall)	23 (100%)	38 (100%)	61 (100%)

Table 4: Comparison between the patients with *Candida albicans* versus patients with *Candida non-albicans* regarding the patient diagnosis while admitting.

ARDS: Acute Respiratory Distress Syndrome.

Regarding isolation site, overall, maximum number of *Candida* spp. were isolated from blood (50; 82.0%), followed by respiratory site (24; 39.3%), and urine (21; 34.4%) (Table 5). The least number of *Candida* spp. were isolated from the sterile body fluids (SBF) (9; 14.8%). Among the two groups *C. albicans* and *C. non-albicans*, relatively, *C. albicans* were isolated from more number of patients as compared to the *C. non-albicans* from blood (21/23 [91.3%] vs 29/38 [76.3%]), respiratory site (11/23 [47.8%] vs 13/38 [34.2%]) and urine (9/23 [39.1%] vs 12/38 [31.6%]). Significant difference between the two groups was observed regarding the isolation site sterile body fluids (SBF), where *C. albicans* was not detected in any case while *C. non-albicans* was isolated from 9 patients (23.7%) (p = 0.01) (Table 5).

Isolation sites	Total patients with candidemia	<i>C. albicans</i>	<i>C. non-albicans</i>	Test of significance	p-value
	N (%) Total = 61 (100%)	N (%) Total = 23 (100%)	N (%) Total = 38 (100%)		
Blood	50 (82%)	21 (91.3%)	29 (76.3%)	$\chi^2 = 2.18$	0.18
SBF	9 (14.8%)	0 (0%)	9 (23.7%)	$\chi^2 = 6.39$	0.01
Respiratory	24 (39.3%)	11 (47.8%)	13 (34.2%)	$\chi^2 = 1.11$	0.29
Urine	21 (34.4%)	9 (39.1%)	12 (31.6%)	$\chi^2 = 0.36$	0.55

Table 5: Comparison between patients with *Candida albicans* versus the patients with *Candida non-albicans* regarding isolation sites. Data are presented as mean ± SD or N (%). SBF: Sterile Body Fluids.

We next analyzed the risk factors associated with the patients suffering from candidiasis. We observed that the difference between the two groups, regarding the risk factors, was not statistically significant. However, the proportion of *C. albicans* patients was higher than *C. non-albicans* ones among the cases with the following risk factors: younger than 5 months (15/23 [65.2%] vs

15/38 [39.5%]), presence of urinary catheter (19/23 [82.6%] vs 28/38 [73.7%]), peritoneal tube (6/23 [26.1%] vs 7/38 [18.4%]), multi organ failure (6/23 [26.1%] vs 9/38 [23.7%]), blood product transfusions (19/23 [82.6%] vs 29/38 [76.3%]), chemotherapy (2/23 [8.7%] vs 0/38 [0.0%]), and chest tubes (3/23 [13.0%] vs 4/38 [10.5%]) (Table 6).

Risk factors	Total patients with candidemia	<i>C. albicans</i>	<i>C. non-albicans</i>	Test of significance	p-value
	N (%) Total = 61 (100%)	N (%) Total = 23 (100%)	N (%) Total = 38 (100%)		
Age (in months)					
Age groups:					
Equal or less than 1.5 months	13 (21.3%)	7 (30.4%)	6 (15.8%)	$\chi^2 = 7.55$	0.08
2 - 5 months	17 (27.9%)	8 (34.8%)	9 (23.7%)		
6-11 months	14 (23%)	5 (21.7%)	9 (23.7%)		
12-36 months	9 (14.8%)	0 (0%)	9 (23.7%)		
Equal or more than 60 months	8 (13.1%)	3 (13%)	5 (13.2%)		
Length of ICU stay (in days)	29.74 (±16.18)	26.52 (±15.77)	31.68 (±16.32)	t = - 1.21	0.23
Mechanical ventilation	With: 54 (88.5%) Without: 7 (11.5%)	With: 20 (87%) Without: 3 (13%)	With: 34 (89.5%) Without: 4 (10.5%)	$\chi^2 = 0.09$	0.99
Duration of ventilation (in days)	20.57 (±14.05)	18.61 (±11.13)	21.76 (±15.57)	t = - 0.92	0.36
Presence of central venous catheter	Present: 59 (96.7%) Absent: 2 (3.3%)	Present: 22 (95.7%) Absent: 1 (4.3%)	Present: 37 (97.4%) Absent: 1 (2.6%)	$\chi^2 = 0.13$	0.99
Presence of urinary catheter	Present: 47 (77%) Absent: 14 (23%)	Present: 19 (82.6%) Absent: 4 (17.4%)	Present: 28 (73.7%) Absent: 10 (26.3%)	$\chi^2 = 0.65$	0.54
Presence of peritoneal tube	Present: 13 (21.3%) Absent: 48 (78.7%)	Present: 6 (26.1%) Absent: 17 (73.9%)	Present: 7 (18.4%) Absent: 31 (81.6%)	$\chi^2 = 0.5$	0.53
Presence of TPN	Present: 46 (75.4%) Absent: 15 (24.6%)	Present: 17 (73.9%) Absent: 6 (26.1%)	Present: 29 (76.3%) Absent: 9 (23.7%)	$\chi^2 = 0.05$	0.83

Multi organ failure	Present: 15 (24.6%) Absent: 46 (75.4%)	Present: 6 (26.1%) Absent: 17 (73.9%)	Present: 9 (23.7%) Absent: 29 (76.3%)	$\chi^2 = 0.05$	0.83
Blood products	Present: 48 (78.7%) Absent: 13 (21.3%)	Present: 19 (82.6%) Absent: 4 (17.4%)	Present: 29 (76.3%) Absent: 9 (23.7%)	$\chi^2 = 0.39$	0.75
Chemotherapy	Present: 2 (3.3%) Absent: 59 (96.7%)	Present: 2 (8.7%) Absent: 21 (91.3%)	Present: 0 (0%) Absent: 38 (100%)	$\chi^2 = 3.45$	0.14
Steroid therapy	Present: 10 (16.4%) Absent: 51 (83.6%)	Present: 2 (8.7%) Absent: 21 (91.3%)	Present: 8 (21.1%) Absent: 30 (78.9%)	$\chi^2 = 1.6$	0.29
Chest tubes	Present: 7 (11.5%) Absent: 54 (88.5%)	Present: 3 (13%) Absent: 20(87%)	Present: 4 (10.5%) Absent: 34 (89.5%)	$\chi^2 = 0.9$	0.99
Number of days of antimicrobial therapy prior to candidemia	18.05 (\pm 10.03)	15.57 (\pm 9.41)	19.55 (\pm 10.22)	t = - 1.52	0.13

Table 6: Comparison between patients with *Candida albicans* versus patients with *Candida non-albicans* regarding risk factors. Data are presented as mean \pm SD or N (%). TPN: Total Parenteral Nutrition.

On the other hand, the rate of *C. non-albicans* was higher than *C. albicans* among the cases with the following risk factors: Length of ICU stay (31.68 vs 26.53 days), central venous catheter (37/38 [97.4%] vs 22/23 [95.7%]), total parenteral nutrition (TPN) (29/38 [76.3%] vs 17/23 [73.9%]), steroid therapy (8/38 [21.1%] vs 2/23 [8.7%]), days of broad-spectrum antimicrobial therapy prior to candidemia (19.55 vs 15.57 days), mechanical ventilation (34/38 [89.5%] vs 20/23 [87.0%]) and duration of ventilation (21.76 vs 18.61 days) (Table 6).

Finally, we studied the outcomes of the patients suffering from candidemia. We found that the mortality rate was higher among the *C. albicans* infected patients than the ones infected with *C. non-albicans* (15/23 [65.2%] vs 17/38 [44.7%]) (Table 7). However, the length of hospitalization and the duration of the treatment with antifungals were relatively higher among *C. non-albicans* than the *C. albicans* infected group, 46.22 vs 44.05 days and 21.95 vs 20.04 days, respectively; the differences were not significant (Table 7).

Parameters	Total patients with candidemia	<i>C. albicans</i>	<i>C. non-albicans</i>	Test of significance	p-value
	Total = 61 (100%) N (%)	Total = 23 (100%) N (%)	Total = 38 (100%) N (%)		
Deceased	32 (52.5%)	15 (65.2%)	17 (44.7%)	$\chi^2 = 2.41$	0.12
Survived	29 (47.5%)	8 (34.8%)	21 (55.3%)		
Length of Hospital stay (in days)	45.43 (\pm 34.18)	44.05 (\pm 43.13)	46.22 (\pm 28.55)	t = - 0.23	0.82
Duration of antifungal treatment (in days)	21.23 (\pm 14.89)	20.04 (\pm 18.06)	21.95 (\pm 12.82)	t = - 0.48	0.63

Table 7: Comparison between the patients with *Candida albicans* versus patients with *Candida non-albicans* regarding outcomes. Data are presented as mean \pm SD or N (%).

Discussion

Aggressive fungal infections such as invasive candidiasis (IC) and invasive aspergillosis (IA) have resulted in an expanding public

health problem globally, including the Arab world [37-39]. These infections burden the healthcare system due to associated high morbidity, mortality, and the cost of care [37,40]. Several factors

related to the patients and environment influence the epidemiology of invasive fungal infections; these factors depend on the geographic region [37-42], and variations are found among continents and countries, or within the same area [37,43].

Our study included 61 pediatric patients with invasive candidiasis from a tertiary medical center in Saudi Arabia. In this study, we attempted to understand the outcomes, mortality rate, and risk factors among the patients of this study group. Among all the patients with candidemia, around two-thirds of the cases had *C. non-albicans* infection, while the remaining one-third had *C. albicans* infection. These results concur with the findings of similar study performed in Saudi Arabia, where *C. non-albicans* cases were more than half (54.3%) of all the cases detected, and the rest of the cases (45.7%) were infected with *C. albicans*. Also, in a large multi-center, multi-national study of pediatric candidiasis, which included 30 participating sites (20 in the US and 10 international), of the 449 *Candida* isolates, *C. albicans* (40%) was the most common species, but collectively, the non-*albicans Candida* species were dominant (60%) [44]. Similarly, in a study conducted in Brazil, it was found that the *C. non-albicans* species accounted for 65.7% of the total cases, while the *C. albicans* species accounted for the rest 34.3% of the cases [9]. Likewise, the most extensive and contemporary retrospective review from a single pediatric center (patients aged 6 months to 18 years old) found that *C. albicans* was the most commonly isolated (44.2%) species during invasive candidemia, followed by *C. parapsilosis* (23.9%) [45]. Further, in a study conducted in Italy, the rate of *C. albicans* infection was found to be 49%, and the prevalence of *C. non-albicans* was 51%, which included species like *C. parapsilosis*, *C. glabrata* and *C. tropicalis* [46].

These results show that despite the fact that *C. albicans* is still the main pathogen associated with candidemia, there is an increase in the rate of infection by *C. non-albicans*, which in turn has become a serious health challenge. This observation has been reported by several other studies and identified different reasons for this phenomenon. The first one is due to the use of fluconazole as prophylaxis [47-49]. Another reason, at least in part, is reflective of more accurate identification of yeast isolates at the species level [6]. However, the reasons for this growth in the rate of *C. non-albicans* are not yet totally understood [46].

In the current study, the primary admitting diagnosis was sepsis, which was observed among a third of the total cases (21; 34.4%). In a study performed in the USA, fungi were the second most com-

mon pathogen to be identified in the cases of sepsis [50,51]. While, in another study, the main underlying condition was found to be malignancies [9].

Although the occurrence of invasive candidiasis is similar in both pediatrics and adults, there were significant differences in the host factors, pharmacokinetics, and outcomes in children than adults [20, 52-56]. Candidiasis excessively affects critically ill children. In a study conducted in the USA, almost 50% of the candidemia cases in children were found to occur in the patients admitted in PICU setting [20]. In addition, other studies also reported higher mortality rate among the children admitted in the PICU [56,57]. The results of the current study are consistent with the previous study, where extended stay in PICU caused *Candida* infections (≥ 45 days).

In a single-center study, Zaoutis., *et al.* reported the presence of a central venous catheter, recent exposure to parenteral nutrition, recent exposure to certain antimicrobial agents vancomycin, anti-aerobic agents and underlying malignancy as the risk factors which are also the clinical predictors of candidemia among pediatric ICU patients (OR-46%; 95% CI- 19% - 75%) [58]. In another study, the most common risk factors identified were the number of antibiotics received prior to candidemia development, previous hemodialysis, recent extensive gastro-abdominal surgery, isolation of *Candida* spp. from sites other than blood, prior use of a Hickman catheter, and the length of ICU stay [46]. Further, in a study conducted in Saudi Arabia, the main predictors of candidemia among the patients in PICU were prematurity, low birth weight, presence of a central venous catheter, malignancy, immunotherapy, and the required use of mechanical ventilators [14]. In the current study, we observed that the main risk factors and predictors of candidemia were age younger than 1 year, presence of a central venous catheter, presence of a urinary catheter, presence of TPN, blood products, required use of mechanical ventilators, and prior treatment with broad-spectrum antimicrobials. These differences in the results could be due to several factors, such as different geographic areas, sample size, and the nature of the studies.

The current study revealed good *in vitro* sensitivity rates of the *Candida* species to the available antifungal medication in the current hospital. In the 61 *Candida* isolates tested for sensitivity, majority of the *C. albicans* and *C. non-albicans* strains showed sensitivity to the following antifungal agents: amphotericin-B, fluconazole, flucytosine, and caspofungin. This susceptibility pattern is similar

to that described in a review by Omrani, *et al.* [59], and Almoosa, *et al.* [14], where they reported good susceptibility patterns to all antifungal medications.

It is well known that *Candida* blood stream infections (BSIs) severely compromise the survival of ICU patients. In the EPIC II survey, it was observed that the patients with candidemia have the highest (42.6%) crude ICU mortality as compared to the patients suffering from Gram-positive (25.3%) and Gram-negative (29.1%) bacterial infections [46]. The overall mortality observed in our study is in agreement with the previous local, regional, and international studies. In their study, Al Thaqafi, *et al.* reported that the patient mortality rate was 50% [33] while, Pfaller, *et al.* observed that there was high crude mortality of 46-75% [24]. Also, in a hospital study conducted in Brazil, the crude mortality among the candidemia patients was found to be 72% [9]. However, a low mortality rate of 36.4% was also reported in a study, which was a deviation from other studies [14]. Although, in the studies conducted in Italy and Greece, increased mortality was reported in patients with *Candida albicans* blood stream infections (BSIs) [46,60], however, other studies did not support this correlation [61, 62]. In the current study, the mortality rate was higher in patients infected with *C. albicans* than *C. non-albicans* spp. (65.2% vs. 44.7%, respectively), which is in agreement with the findings of most of the earlier studies.

Conclusion

Although *Candida albicans* is the most commonly isolated *Candida* species, infections due to non-*albicans* species are increasing. In general, invasive candidiasis has a poor clinical prognostic outcome in the Kingdom of Saudi Arabia. This study has shown that a lower proportion of deaths occur within the non-*albicans* infected group of patients. The study's main limitation is its retrospective nature and the dependence on the data obtained from one hospital only. Nonetheless, our findings also highlight the common indicators that may guide early prophylactic intervention. There is a need for more retrospective and detailed multi-center studies to enable the medical community better define the risks and optimal strategies for the early diagnosis of candidemia.

Conflict of Interest

The authors declare no competing financial interest. Furthermore, the work was not supported or funded by any drug company.

Bibliography

1. Guinea J. "Global trends in the distribution of *Candida* species causing candidemia". *Clinical Microbiology and Infection* 20.6 (2014): 5-10.
2. Martin GS, *et al.* "The epidemiology of sepsis in the United States from 1979 through 2000". *The New England Journal of Medicine* 348.16. (2003): 1546-1554.
3. Lepak A and Andes D. "Fungal sepsis: optimizing antifungal therapy in the critical care setting". *Critical Care Clinics* 27.1 (2011): 123-147.
4. Kaushik A and Kest H. "The role of antifungals in pediatric critical care invasive fungal infections". *Critical Care Research and Practice* (2018): 8469585.
5. Hawksworth DL. "The magnitude of fungal diversity: the 1.5 million species estimate revisited". *Mycological Research* 105.12 (2001): 1422-1432.
6. Pfaller MA and Diekema DJ. "Epidemiology of invasive candidiasis: a persistent public health problem". *Clinical Microbiology Reviews* 20.1 (2007): 133-163.
7. Mesini A, *et al.* "Candida infections in paediatrics: Results from a prospective single-centre study in a tertiary care children's hospital". *Mycoses* 60.2 (2017): 118-123.
8. Playford EG, *et al.* "Prophylaxis, empirical and preemptive treatment of invasive candidiasis". *Current Opinion in Critical Care* 16.5 (2010): 470-474.
9. Doi AM, *et al.* "Epidemiology and microbiologic characterization of nosocomial candidemia from a Brazilian national surveillance program". *PloS one* 11.1 (2016): e0146909.
10. Pfaller MA, *et al.* "Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of *Candida* species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing". *Journal of Clinical Microbiology* 45.6 (2007): 1735-1745.
11. Colombo AL, *et al.* "Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period". *Intensive Care Medicine* 40.10 (2014): 1489-1498.
12. Ahmed A, *et al.* "Risk prediction for invasive candidiasis". *Indian Journal of Critical Care Medicine* 18.10 (2014): 682-688.

13. Delaloye J and Calandra T. "Invasive candidiasis as a cause of sepsis in the critically ill patient". *Virulence* 5.1 (2014): 161-169.
14. Almoosa Z., et al. "Invasive Candidiasis in pediatric patients at King Fahad Medical City in Central Saudi Arabia. A 5-year retrospective study". *Saudi Medical Journal* 38.11 (2017): 1118-1124.
15. Lortholary O., et al. "Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)". *Intensive Care Medicine* 40.9 (2014): 1303-1312.
16. Bassetti M., et al. "A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality". *Intensive Care Medicine* 40.6 (2014): 839-845.
17. Falagas ME., et al. "Relative frequency of albicans and the various non-albicans *Candida* spp among candidemia isolates from inpatients in various parts of the world: a systematic review". *International Journal of Infectious Diseases* 14.11 (2010): e954-966.
18. Falagas ME., et al. "Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies". *European Journal of Clinical Microbiology and Infectious Diseases* 25.7 (2006): 419-425.
19. Gudlaugsson O., et al. "Attributable mortality of nosocomial candidemia, revisited". *Clinical Infectious Diseases* 37.9 (2003): 1172-1177.
20. Zaoutis TE., et al. "The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis". *Clinical Infectious Diseases* 41.9 (2005): 1232-1239.
21. Colombo AL., et al. "*Candida glabrata*: an emerging pathogen in Brazilian tertiary care hospitals". *Medical Mycology* 54.1 (2013): 38-44.
22. Nucci M., et al. "Epidemiology of opportunistic fungal infections in Latin America". *Clinical Infectious Diseases* 51.5 (2010): 561-570.
23. Abi-Said D., et al. "The epidemiology of hematogenous candidiasis caused by different *Candida* species". *Clinical Infectious Diseases* 24.6 (1997): 1122-1128.
24. Pfaller MA., et al. "Epidemiology and outcomes of invasive candidiasis due to non-albicans species of *Candida* in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008". *PloS one* 9.7 (2014): e101510.
25. Chowdhary A., et al. "Multidrug-resistant endemic clonal strain of *Candida auris* in India". *European Journal of Clinical Microbiology and Infectious Diseases* 33.6 (2014): 919-926.
26. Pfaller MA., et al. "Variation in *Candida* spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009)". *Diagnostic Microbiology and Infectious Disease* 68.3 (2010): 278-283.
27. Cuenca-Estrella M., et al. "Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds". *Antimicrobial Agents and Chemotherapy* 53.5 (2009): 2192-2195.
28. Pfaller MA., et al. "Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among *Candida* bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)". *Journal of Clinical Microbiology* 49.1 (2011): 396-399.
29. Arendrup MC and Perlin DS. "Echinocandin resistance: an emerging clinical problem?". *Current Opinion in Infectious Diseases* 27.6 (2014): 484-492.
30. Souza AC., et al. "*Candida parapsilosis* resistance to fluconazole: Molecular mechanisms and in vivo impact in infected *Galleria mellonella* larvae". *Antimicrobial Agents and Chemotherapy* 59.10 (2015): 6581-6587.
31. Castanheira M., et al. "Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections". *International Journal of Antimicrobial Agents* 44.4 (2014): 320-326.
32. Pappas PG., et al. "Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America". *Clinical Infectious Diseases* 62.4 (2016): e1-50.
33. Al Thaqafi AH., et al. "Predictors and outcomes of *Candida* bloodstream infection: eight-year surveillance, western Saudi Arabia". *International Journal of Infectious Diseases* 21. (2014): 5-9.
34. Guery BP., et al. "Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment". *Intensive Care Medicine* 35.2 (2009): 206-214.
35. Guery BP., et al. "Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis". *Intensive Care Medicine* 35.1 (2009): 55-62.

36. Seng P, et al. "Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry". *Clinical Infectious Diseases* 49.4 (2009): 543-551.
37. Kmeid J, et al. "Epidemiology and burden of invasive fungal infections in the countries of the Arab League". *Journal of Infection and Public Health* (2019).
38. Alothman AF, et al. "Burden and treatment patterns of invasive fungal infections in hospitalized patients in the Middle East: real-world data from Saudi Arabia and Lebanon". *Infection and Drug Resistance* 10. (2017): 35-41.
39. Alothman AF, et al. "Clinical practice guidelines for the management of invasive *Candida* infections in adults in the Middle East region: Expert panel recommendations". *Journal of Infection and Public Health* 7.1 (2014): 6-19.
40. Kim A, et al. "Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States". *Mycoses* 54.5 (2011): e301-12.
41. Webb BJ, et al. "Epidemiology and clinical features of invasive fungal infection in a US health care network". *Open Forum Infectious Diseases* 5.8 (2018): ofy187.
42. Enoch DA, et al. "Invasive fungal infections: a review of epidemiology and management options". *Journal of Medical Microbiology* 55.7 (2006): 809-818.
43. Horn DL, et al. "Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry". *Clinical Infectious Diseases* 48.12 (2009): 1695-1703.
44. Palazzi DL, et al. "Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study". *The Pediatric Infectious Disease Journal* 33.12 (2014): 1294-1296.
45. Dutta A and Palazzi DL. "Candida non-albicans versus *Candida albicans* fungemia in the non-neonatal pediatric population". *The Pediatric Infectious Disease Journal* 30.8 (2011): 664-668.
46. Montagna MT, et al. "Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013". *European Review for Medical and Pharmacological Sciences* 18.5 (2014): 661-674.
47. Chow JK, et al. "Factors associated with candidemia caused by non-albicans *Candida* species versus *Candida albicans* in the intensive care unit". *Clinical Infectious Diseases* 46.8 (2008): 1206-1213.
48. Playford EG, et al. "Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans *Candida* spp". *Critical Care Medicine* 36.7 (2008): 2034-2039.
49. Bassetti M, et al. "Epidemiological trends in nosocomial candidemia in intensive care". *BMC Infectious Diseases* 6. (2006): 21.
50. Wisplinghoff H, et al. "Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities". *The Pediatric Infectious Disease Journal* 22.8 (2003): 686-691.
51. Watson RS, et al. "The epidemiology of severe sepsis in children in the United States". *American Journal of Respiratory and Critical Care Medicine* 167.5 (2003): 695-701.
52. Pfaller MA, et al. "Trends in antifungal susceptibility of *Candida* spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000". *Journal of Clinical Microbiology* 40.3 (2002): 852-856.
53. Krcmery V, et al. "Aetiology, antifungal susceptibility, risk factors and outcome in 201 fungaemic children: data from a 12-year prospective national study from Slovakia". *Journal of Medical Microbiology* 51.2 (2002): 110-116.
54. Hope WW, et al. "Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing". *Antimicrobial Agents and Chemotherapy* 51.10 (2007): 3714-3719.
55. Blyth CC, et al. "Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients". *Pediatrics* 123.5 (2009): 1360-1368.
56. Zaoutis TE, et al. "Risk factors for mortality in children with candidemia". *The Pediatric Infectious Disease Journal* 24.8 (2005): 736-739.
57. Singhi SC, et al. "Candidemia in a pediatric intensive care unit". *Pediatric Critical Care Medicine* 5.4 (2004): 369-374.
58. Zaoutis TE, et al. "Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention". *Clinical Infectious Diseases* 51.5 (2010): e38-45.

59. Omrani AS., *et al.* "Ten-year review of invasive *Candida* infections in a tertiary care center in Saudi Arabia". *Saudi Medical Journal* 35.8 (2014): 821-826.
60. Dimopoulos G., *et al.* "Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome". *Anesthesia and Analgesia* 106.2 (2008): 523-529.
61. Holley A., *et al.* "Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units". *International Journal of Antimicrobial Agents* 33.6 (2009): 554.e1-554.e7.
62. Montagna MT., *et al.* "Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)". *Infection* 41.3 (2013): 645-653.

Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

Website: www.actascientific.com/

Submit Article: www.actascientific.com/submission.php

Email us: editor@actascientific.com

Contact us: +91 9182824667